What is the difference in presentation between ABO (A and B blood group antigens and antibodies) incompatibility and delayed hemolytic transfusion reaction (DHTR)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ABO Incompatibility vs Delayed Hemolytic Transfusion Reaction: Key Presentation Differences

ABO incompatibility presents immediately (within minutes to hours) with acute intravascular hemolysis, shock, and DIC, while delayed hemolytic transfusion reaction (DHTR) occurs 6-21 days post-transfusion with extravascular hemolysis, fever, jaundice, and often a paradoxical drop in hemoglobin below pre-transfusion levels.

Timing: The Most Critical Distinguishing Feature

ABO incompatibility is an acute hemolytic transfusion reaction occurring within 24 hours (typically within minutes) of transfusion 1.

DHTR manifests within 21 days post-transfusion, with most cases presenting around 6-8 days after blood administration 2, 3.

Clinical Presentation Differences

ABO Incompatibility (Acute Hemolytic Reaction)

Immediate symptoms include 1:

  • Pain (chest, back, infusion site)
  • Restlessness and anxiety
  • Skin flushing
  • Dyspnea
  • Shock (hypotension, tachycardia)
  • Nausea

Severe complications develop rapidly 1:

  • Intravascular hemolysis with immediate hemoglobinuria
  • Disseminated intravascular coagulation (DIC) with microvascular bleeding
  • Acute renal failure
  • Cardiovascular collapse

The pathophysiology involves complement activation (C3a, C5a) causing histamine and kinin release, leading to vasomotor instability and activation of the coagulation cascade 1.

Delayed Hemolytic Transfusion Reaction

Subacute presentation includes 2, 4, 3:

  • Fever (high-grade, present in nearly all cases)
  • Jaundice (yellowing of skin and sclera from bilirubin accumulation)
  • Hemoglobinuria (dark or red-colored urine)
  • Bone pain that can mimic vaso-occlusive crisis in sickle cell patients
  • Profound anemia (median hemoglobin 49 g/L in pediatric series)

Laboratory hallmarks distinguish DHTR 2, 5, 3:

  • Inadequate hemoglobin rise (<1 g/dL post-transfusion) or rapid fall back to pre-transfusion levels
  • Significant LDH elevation (median 2239 IU/L) reflecting red cell destruction
  • Relative reticulocytopenia or paradoxical reticulocytosis from baseline
  • In sickle cell patients: accelerated HbS% increase with concomitant fall in HbA
  • New red cell alloantibody detected (though notably absent in 49% of cases) 3

Mechanism of Hemolysis

ABO incompatibility: Intravascular hemolysis mediated by complement-fixing IgM antibodies causing immediate red cell lysis within the circulation 1.

DHTR: Primarily extravascular hemolysis mediated by IgG alloantibodies (commonly Kidd, Rh, Kell antigens), with red cells destroyed in the spleen and liver 6, 7.

Hyperhemolysis: The Most Severe DHTR Variant

Hyperhemolysis syndrome represents the most dangerous form of DHTR, where hemoglobin rapidly declines below the pre-transfusion level, indicating destruction of both transfused AND the patient's own red blood cells 2, 4, 7. This phenomenon does not occur with ABO incompatibility.

Monitoring in Anesthetized Patients

Critical difference: In anesthetized patients receiving transfusions, ABO incompatibility presents with hypotension, tachycardia, hemoglobinuria, and microvascular bleeding that require immediate recognition 2. DHTR would not manifest during the operative period but days later.

Common Pitfall

Do not confuse the timing: The key error is failing to recognize that ABO incompatibility is a medical emergency occurring during or immediately after transfusion, while DHTR is a delayed complication requiring high clinical suspicion when patients present with unexplained anemia and hemolysis days to weeks post-transfusion 2, 1. In DHTR, the antibody may be undetectable on initial screening (antibody evanescence), making diagnosis challenging 8, 3.

References

Research

Clinical presentation of haemolytic transfusion reactions.

Anaesthesia and intensive care, 1980

Guideline

Delayed Hemolytic Transfusion Reaction Diagnosis and Presentation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Delayed Hemolytic Transfusion Reaction: Clinical Presentation and Characteristics

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Delayed Hemolytic Transfusion Reaction (DHTR)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Delayed haemolytic transfusion reaction due to Kidd antibodies.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.